Table 2.
Overview of clinical trials evaluating the efficacy of low-dose whole-lung irradiation in patients with COVID-19 pneumonia
| Clinical trial | RESCUE 1-19 | COLOR-19 | Present trial | VENTED |
|---|---|---|---|---|
| NCT number | NCT04366791 | NCT04377477 | NCT04390412 | NCT04427566 |
| Start date | April 29, 2020 | May 6, 2020 | May 15, 2020 | June 11, 2020 |
| Country of origin | United States | Italy | Iran | United States |
| Current status | Preliminary results are published in a non–peer reviewed journal | Recruiting patients | Pilot study (published) | Recruiting patients |
| Participants | ||||
| Sex | Male and female | Male and female | Male and female | Male and female |
| Age, y | ≥18 | ≥50 | >60 | ≥18 |
| Clinical presentation | Receiving O2 with NIV | Receiving O2 with NIV | Receiving O2 with NIV | Receiving O2 with MV |
| No. of participants | 5 | 30 | 5 (for pilot study) | 24 |
| Treatment plan | Single-fraction whole-lung irradiation | Single-fraction whole-lung irradiation | Single-fraction whole-lung irradiation + national guideline | Single-fraction whole-lung irradiation |
| Radiation dose, Gy | 1.5 | 0.7 (on average) | 0.5 (+ an additional 0.5 if needed) | 0.8 |
| Primary objectives | Safety Clinical recovery |
Length of hospital stay No. of ICU admissions |
Change in blood oxygenation Length of hospital/ICU stay |
Mortality rate after 30 d of ICU-based MV initiation |
Abbreviations: ICU = intensive care unit; MV = mechanical ventilation; NIV = noninvasive ventilation.